Has Daniel Behroozan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $138,798 in general payments to Daniel Behroozan, MD across 730 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Behroozan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Behroozan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Behroozan, MD

Dermatology · Santa Monica, CANPI 1851325716

Payments from drug & device makers

$138,798in general payments, 2019–2025

Across 730 payments — averaging $190.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Galderma Laboratories, L.p.$96K
Pfizer$23K
AbbVie$10K
Biofrontera Inc.$2K
Amgen$1K
Incyte Corporation$755
plus $6K from 36 others

What the payments were for

Consulting fees$1,5001%
Speaking & faculty fees$113,19382%
Travel & lodging$4,0133%
Food & beverage$19,86014%
Education$2320%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Galderma Laboratories, L.p.	210	$95,931
Pfizer	54	$23,270
AbbVie(2 entities)	166	$9,805
Biofrontera Inc.	3	$1,548
Amgen	60	$1,492
Incyte Corporation	24	$755
Arcutis Biotherapeutics, Inc.	19	$749
Dermavant Sciences, Inc.	15	$609
Ortho Dermatologics, A Division Of Bausch Health US, LLC	35	$563
Journey Medical Corporation	15	$524
LEO Pharma Inc.	19	$420
Almirall LLC	9	$386
Sun Pharmaceutical Industries Inc.	14	$328
EPI Health, LLC	4	$261
Merz North America, Inc.	4	$247
Mayne Pharma Commercial LLC	12	$178
Sanofi	7	$170
Regeneron Healthcare Solutions, Inc.	5	$165
Bristol Myers Squibb	5	$136
Revance Therapeutics, Inc.	1	$131
Sandoz	6	$128
Sanofi-aventis U.S. LLC	2	$105
Dermira, Inc.	5	$99
Mimedx Group, Inc.	4	$93
Prugen, Inc. Pharmaceuticals	6	$85
Solta Medical, A Division Of Bausch Health US, LLC	4	$84
Endo Pharmaceuticals Inc.	1	$68
Organon	3	$61
Lilly USA, LLC	2	$54
Organogenesis Inc.	2	$53
Medimetriks Pharmaceuticals, Inc.	2	$51
Johnson & Johnson	2	$47
Mindera Corp	1	$37
Misonix Inc	1	$25
DUSA Pharmaceuticals, Inc.	1	$23
Mission Pharmacal Company	1	$21
VYNE Pharmaceuticals Inc.	1	$19
Novartis	1	$18
Bioventus LLC	1	$17
Botanix SB Inc	1	$17
Aclaris Therapeutics, Inc.	1	$15
Merck	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AKLIEF$77,825
TWYNEO$37,248
ORACEA$24,515
EPSOLAY$24,024
EPIDUO FORTE$11,825
EUCRISA$8,192
CIBINQO$6,500
AMELUZ$1,500
BF-RhodoLED$1,500
XEPI$1,500
BOTOX$840
VTAMA$358
Klisyri$261
Otezla$242
OPZELURA$228
Sitavig$209
Cloderm$209
Minolira 105mg$209
Minolira 135mg$209
Rhofade$209

How this compares

$138,798 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California →

Medicare billing

Part B allowed, 2024

$591,074

Medicare patients

508

Services billed

2,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluorouracil	16	$796
Cephalexin	94	$402
Ketoconazole	18	$235
Mupirocin	23	$195
Doxycycline Hyclate	15	$111
Azithromycin	14	$91
Triamcinolone Acetonide	11	$38

Paid to pharmacies, not to this prescriber.

Other dermatology in Santa Monica

Paul YamauchiSanta Monica$7.8M
David StollSanta Monica$2.3M
Ava ShambanSanta Monica$1.5M
Vivian LaquerIrvine$20.9M
Howard SofenLos Angeles$16.1M
Raja SivamaniSacramento$11.8M
Jennifer SoungSanta Ana$10.3M
Stacy SmithEncinitas$7.9M
Navid EzraThousand Oaks$7.8M
Paul WallaceBeverly Hills$7.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →